DIVALPROEX 500 MG — DIN 02400510
VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG · SANIS HEALTH INC · TABLET (ENTERIC-COATED) · wholesale supply in Canada
Health Canada status: DORMANT
What is DIVALPROEX?
DIVALPROEX 500 MG contains VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02400510, held by SANIS HEALTH INC, supplied as TABLET (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is DIVALPROEX used for?
Treatment of simple or complex absence seizures, primary generalized seizures with tonic-clonic manifestations, and acute manic episodes associated with bipolar disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Valproic Acid cost around the world?
Valproic Acid is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Czechia | max producer price (ex-factory) | 8 | 24 |
| South Africa | single exit price | 22 | 22 |
| Austria | KVP (Kassenverkaufspreis) | 13 | 13 |
| Greece | producer price (ex-factory) | 9 | 9 |
| Luxembourg | reimbursement | 7 | 7 |
| Bahrain | retail (max) | 3 | 6 |
| United Kingdom | hospital | 6 | 6 |
| United Arab Emirates | public | 5 | 5 |
| Saudi Arabia | public | 2 | 2 |
94 pack listings across 75 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Valproic Acid pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Valproic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
18 holders have a Canadian DIN containing Valproic Acid, across 70 DINs, of which 17 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 10 | 4 | APO-DIVALPROEX, APO-VALPROIC ACID, APO-VALPROIC ACID ORAL SOLUTION, DIVALPROEX, VALPROIC ACID, +1 more | Sourceable in Canada |
| BGP PHARMA ULC | 5 | 4 | DEPAKENE, EPIVAL | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 7 | 3 | MYL-DIVALPROEX, MYLAN-DIVALPROEX, MYLAN-VALPROIC | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 4 | 3 | JAMP DIVALPROEX, JAMP VALPROIC ACID ORAL SOLUTION | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 2 | PMS-DIVALPROEX (125MG), PMS-DIVALPROEX (250MG), PMS-DIVALPROEX (500MG), PMS-VALPROIC ACID, PMS-VALPROIC ACID E.C. | Sourceable in Canada |
| ODAN LABORATORIES LTD | 1 | 1 | ODAN-VALPROIC ACID | Sourceable in Canada |
| TEVA CANADA LIMITED | 7 | 0 | NOVO-VALPROIC, RATIO-VALPROIC, TEVA-DIVALPROEX | No marketed DIN |
| DOMINION PHARMACAL | 6 | 0 | DOM-DIVALPROEX, DOM-VALPROIC ACID, DOM-VALPROIC ACID E.C. | No marketed DIN |
| PHARMEL INC | 6 | 0 | PHL-DIVALPROEX, PHL-VALPROIC ACID, PHL-VALPROIC ACID E.C. | No marketed DIN |
| PRO DOC LIMITEE | 4 | 0 | DIVALPROEX-125, DIVALPROEX-250, DIVALPROEX-500, VALPROIC-250 | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-VALPROIC - ECC 500MG, RATIO-VALPROIC 50MG/ML SYRUP, RATIO-VALPROIC-CAP 250MG | No marketed DIN |
| SANIS HEALTH INC | 3 | 0 | DIVALPROEX | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET (ENTERIC-COATED) |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section). |
| Storage | Not explicitly detailed in the provided text (refers to STORAGE AND STABILITY section). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Valproic Acid |
|---|---|
| ATC code | N03AG01 |
| AHFS class | 28:12.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02400510 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2400510 |
| Brand name | DIVALPROEX |
| Generic / active ingredient | VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG |
| Market authorization holder | SANIS HEALTH INC |
| Health Canada schedule | Prescription |
| ATC code | N03AG01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AG |
| Current status | DORMANT |
| Status date | 31-Jul-2017 |
| Original market date | 2013-02-13 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered orally. For epilepsy, used as sole or adjunctive therapy. For acute mania, treatment of manic episodes associated with bipolar disorder. Dosage should be titrated to the lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hepatic disease or significant hepatic dysfunction; known hypersensitivity to the drug; known urea cycle disorders.
Warnings and precautions
Serious/fatal hepatotoxicity (especially in children <2 and first 6 months); life-threatening pancreatitis; teratogenicity; suicidal ideation/behaviour; multi-organ hypersensitivity.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
17 of 70 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | 02239699 |
| APO-DIVALPROEX | 125 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | 02239698 |
| APO-DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | 02239700 |
| APO-VALPROIC ACID | 250 MG | CAPSULE | APOTEX INC | MARKETED | 02238048 |
| DEPAKENE | 250 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | 00443832 |
| EPIVAL | 500 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | 00596434 |
| EPIVAL | 250 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | 00596426 |
| EPIVAL | 125 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | 00596418 |
| JAMP DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | 02551152 |
| JAMP DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | 02551160 |
2 · Same class — other molecules in ATC N03AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valproic Acid | APO-DIVALPROEX · APO-VALPROIC ACID · APO-VALPROIC ACID ORAL SOLUTION · DEPAKENE · +38 more | 70 | 17 | Yes |
| Vigabatrin | SABRIL · SABRIL PWR 1G/SACHET · SABRIL PWR 2G/SACHET · SABRIL PWR 3G/SACHET | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AX | Brivaracetam · Cannabidiol · Cenobamate · Lacosamide · Lamotrigine · +4 more | 391 | 197 |
| N03AF | Carbamazepine · Eslicarbazepine · Oxcarbazepine · Rufinamide | 86 | 33 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DIVALPROEX called?
The same molecule, Valproic Acid, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CONVULEX | Latin | Czechia |
| DEPAKINE | Latin | Bahrain, Czechia |
| DEPAKINE CHRONO | Latin | Bahrain, Czechia |
| ORFIRIL | Latin | Czechia |
| ORFIRIL LONG | Latin | Czechia |
| VALPROAT RATIOPHARM CHRONO | Latin | Czechia |
| CONVULEX CR | Latin | Czechia |
| VALPROAT CHRONO SANDOZ | Latin | Czechia |
| Cerepiv IV | Latin | South Africa |
| Convulex Syrup | Latin | South Africa |
| EPIVAL | Latin | Bahrain |
| Sodium Valproate | Latin | Saudi Arabia |
| Votellaz | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Valproic Acid called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Valproic Acid, published to help those searches reach this page.
| Language | Valproic Acid |
|---|---|
| Arabic العربية | حمض الفالبرويك |
| Spanish Español | ácido valproico |
| French Français | acide valproïque |
| German Deutsch | Valproinsäure |
| Japanese 日本語 | バルプロ酸 |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.